个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Tingting[1] * ; Tian Weiwei[2] * ; Wei Shuang[3,4,5] * ; Lu Xinyi[2,5] ; An Jing[6] ; He Shaolong[2,5] ; Zhao Jie[2,5] ; Gao Zhilin[2,5] ; Li Li[1,5] ; Lian Ke[1,5] ; Zhou Qiang[7,8] ; Zhang Huilai[9] ; Wang Liang[10] ; Su Liping[11] ; Kang Huicong[12,13] ; Niu Ting[14] ; Zhao Ailin[14] ; Pan Jing[15] ; Cai Qingqing[16] ; Xu Zhenshu[17] ; Chen Wenming[18] ; Jing Hongmei[19] ; Li Peng[20] ; Zhao Wanhong[21] ; Cao Yang[22,23] ; Mi Jianqing[24] ; Chen Tao[25] ; Chen Yuan[26,27] ; Zou Ping[28] ; Lukacs-Kornek Veronika[29] ; Kurts Christian[29] ; Li Jian[29] ; Liu Xiansheng[30,31] ; Mei Qi[32,33] ; Zhang Yicheng[34,35] ; Wei Jia[36,37,38,39] ;
机构： [1]Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [2]Department of Hematology, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [3]Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [4]Department of Respiratory and Critical Care Medicine, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [5]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, Shanxi, China. [6]School of Public Health, Shanxi Medical University, Taiyuan, 030000, Shanxi, China. [7]Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [8]Department of Cardiovascular Medicine, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [9]Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China. [10]Department of Hematology, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China. [11]Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [12]Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [13]Department of Neurology, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [14]Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. [15]State Key Laboratory of Experimental Hematology, Boren Biotherapy Translational Laboratory, Boren Clinical Translational Center, Beijing GoBroad Boren Hospital, Beijing, 100070, China. [16]Sun Yat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, China. [17]Hematology Department, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fuzhou, 350001, Fujian, China. [18]Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. [19]Department of Hematology, Peking University Third Hospital, Beijing, 100191, China. [20]Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510535, Guangdong, China. [21]Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shanxi, China. [22]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [23]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China. [24]Shanghai Institute of Hematology, Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. [25]Department and Institute of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [26]Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [27]Department of Geriatrics, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [28]Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China. [29]Institute of Molecular Medicine and Experimental Immunology, University Clinic of Rheinische Friedrich-Wilhelms-University, 53111, Bonn, Germany. [30]Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [31]Department of Respiratory and Critical Care Medicine, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [32]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, Shanxi, China. [33]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [34]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [35]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China. [36]Department of Hematology, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [37]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, Shanxi, China. [38]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [39]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China.
出处：
DOI： 10.1186/s40164-023-00426-x
ISSN：

关键词： SARS-CoV-2 COVID-19 CAR T-cell Hematological malignancies Treatment Recommendations

摘要：
The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.© 2023. The Author(s).

基金：
This work was supported by grants from the National High Technology Research and Development Program of China (No. 2021YFA1101504 to Dr. Yicheng Zhang), the National Natural Science Foundation of China (No. 82070217 to Dr. Jia Wei and No. 82270175 to Dr. Zhenshu Xu), Sino-German Center for Research Promotion (SGC)’s rapid Response Funding for Bilateral Collaborative Proposals Between China and Germany in COVID-19 Related Research (No. C-0065 to Dr. Jian Li and Dr. Qi Mei), 2023 COVID-19 Emergency Project of Shanxi Health Commission (No. 2023XG001 to Dr. Xiansheng Liu and No. 2023XG005 to Dr. Shuang Wei), 2023 COVID-19 Emergency Project of Shanxi Bethune Hospital (No. 2023xg02 to Dr. Qi Mei and No. 2023xg05-2 to Dr. Weiwei Tian) and Natural Science Foundation of Fujian Province of China (No. 2021J02040 to Dr. Zhenshu Xu).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 HEMATOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China.
共同第一作者：
通讯作者：
通讯机构： [30]Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [31]Department of Respiratory and Critical Care Medicine, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [32]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, Shanxi, China. [33]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [34]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [35]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China. [36]Department of Hematology, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. [37]Sino-German Joint Oncological Research Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, 030032, Shanxi, China. [38]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. [39]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China.
推荐引用方式(GB/T 7714)：
Zhang Tingting,Tian Weiwei,Wei Shuang,et al.Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era[J].Experimental Hematology & Oncology.2023,12(1):66.doi:10.1186/s40164-023-00426-x.
APA：
Zhang Tingting,Tian Weiwei,Wei Shuang,Lu Xinyi,An Jing...&Wei Jia.(2023).Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.Experimental Hematology & Oncology,12,(1)
MLA：
Zhang Tingting,et al."Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era".Experimental Hematology & Oncology 12..1(2023):66

相关文献

[1]环境卫生与监测：新常态下防控COVID-19的双轮效应思考 [2]Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. [3]Animal models for SARS-CoV-2 infection and pathology. [4]An integrative analysis identifying transcriptional features and key genes involved in COVID-19. [5]A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. [6]Discovery and Nanosized Preparations of (S,R)-Tylophorine Malate as Novel anti-SARS-CoV-2 Agents. [7]Can We Use mTOR Inhibitors for COVID-19 Therapy? [8]Fast construction of SARS-CoV-2 associated plasmid library using parallel cloning method [9]SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights [10]SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号